VBL Therapeutics Announces Patient Dosing Initiated in Randomized, Controlled and Blinded Trial of VB-111 in Patients with Recurrent Glioblastoma Multiforme
VBL Therapeutics (Nasdaq: VBLT) has initiated patient dosing for a Phase 2 clinical trial of ofranergene obadenovec (VB-111) aimed at treating recurrent glioblastoma multiforme (rGBM). The trial, sponsored by Dana-Farber Cancer Institute, will take place across seven U.S. medical centers. It builds on previous successful trials and includes comparisons to standard care. Key endpoints include progression-free survival and overall survival metrics. VB-111 has shown promise in its dual-targeting approach and has received multiple designations for its therapeutic potential.
- Initiation of patient dosing in Phase 2 clinical trial for VB-111 targeting rGBM.
- Collaboration with Dana-Farber Cancer Institute and seven medical centers enhances credibility.
- Previous Phase 2 trial indicated significant survival benefits.
- Clinical trial results are uncertain and may not predict future outcomes.
- Financial and regulatory risks associated with ongoing clinical trials.
Investigator-sponsored study will be conducted at seven centers in the U.S.
TEL AVIV, Israel, March 01, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that patient dosing has been initiated in a Phase 2 clinical trial investigating ofranergene obadenovec (VB-111) for the treatment of recurrent glioblastoma multiforme (rGBM). The study is sponsored by Dana-Farber Cancer Institute and is being conducted through a collaboration between VBL and seven leading neuro-oncology medical centers in the U.S.
“This new study builds upon our previous successful Phase 2 trial of VB-111 in recurrent glioblastoma (rGBM) while incorporating lessons learned from the GLOBE study,” said Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics. “It will use the same VB-111 treatment regimen that induced significant survival benefit in our prior Phase 2 study, this time in patients that go through a second tumor resection. I believe that our perseverance could lead to renewed hope for rGBM patients who are in desperate need of therapies that may change their disease course and prolong life."
The Phase 2 study is enrolling patients with rGBM who are scheduled to undergo a second surgery. VB-111 will be administered either before and after surgery (neo-adjuvant and adjuvant therapy) or after surgery only (adjuvant therapy) and each arm will be compared to a standard of care control arm. In addition to endpoints of progression-free survival (PFS) at 6 months and overall survival (OS), collection of tumor specimens will allow important analysis of the activity of VB-111 within the tumor and will evaluate its effect on the immune system in this immunologically `cold` tumor. Additional information about the new VB-111 study can be found on ClinicalTrials.gov (NCT04406272).
About VB-111 (ofranergene obadenovec)
VB-111 is an investigational, first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. VB-111 is a unique biologic agent that uses a dual mechanism to target solid tumors. Its mechanism combines blockade of tumor vasculature with an anti-tumor immune response. VB-111 is administered as an IV infusion once every 6-8 weeks. It has been observed to be well-tolerated in >300 cancer patients and demonstrated activity signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. VB-111 has received an Orphan Designation for the treatment of ovarian cancer from the European Commission. VB-111 has also received orphan drug designation in both the U.S. and Europe, and fast track designation in the U.S. for prolongation of survival in patients with rGBM. VB-111 successfully demonstrated proof-of-concept and survival benefit in Phase 2 clinical trials in radioiodine-refractory thyroid cancer (NCT01229865) and recurrent platinum-resistant ovarian cancer (NCT01711970).
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications. VBL has developed three platform technologies: a gene-therapy based technology for targeting newly formed blood vessels with focus on cancer, an antibody-based technology targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the Lecinoxoids, a family of small-molecules for immune-related indications. VBL’s lead oncology product candidate, ofranergene obadenovec (VB-111), is an investigational, first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. VB-111 is currently being studied in a VBL-sponsored Phase 3 potential registration trial for platinum-resistant ovarian cancer.
Forward Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. These forward-looking statements may include, but are not limited to, statements regarding our programs, including VB-111, including their clinical development, therapeutic potential and clinical results. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical clinical trial results may not be predictive of future trial results, that our financial resources do not last for as long as anticipated, and that we may not realize the expected benefits of our intellectual property protection. In particular, the DSMC recommendation that the OVAL trial proceed is not assurance that the trial will meet its primary endpoint of overall survival once completed, or that we will obtain positive results to support further development of this candidate. A further list and description of these risks, uncertainties and other risks can be found in our regulatory filings with the U.S. Securities and Exchange Commission, including in our annual report on Form 20-F for the year ended December 31, 2019, and subsequent filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
CONTACT:
Burns McClellan for VBL Therapeutics
Lee Roth (investors) / Ryo Imai (media)
lroth@burnsmc.com / rimai@burnsmc.com
+1-212-213-0006
FAQ
What is the purpose of VBLT's Phase 2 clinical trial?
When was patient dosing initiated for the VB-111 trial?
Who is sponsoring the Phase 2 trial for VB-111?
What are the primary endpoints of the VB-111 study?
What is the significance of VB-111 in cancer treatment?
